摘要
目的观察乳黄制剂对肝硬化模型大鼠晚期糖基化终末产物(AGEs)的影响。方法用四氯化碳(CCl4)复合因素法制造肝硬化模型大鼠,分组治疗后观察肝脏组织病理学变化,用酶联免疫分析法(ELISA)定量测定大鼠肝组织匀浆AGEs的含量。结果乳黄制剂可明显降低肝硬化模型大鼠AGEs含量水平(P<0.05);预防组和模型治疗组肝组织的肝硬化以及纤维组织增生、炎性细胞浸润程度得到改善,其中预防组肝组织的病理变化改善明显。结论乳黄制剂能有效降低肝组织中AGEs的水平,有利于肝硬化程度的好转。
Objective On the existing experimental basis,to further study Ruhuang preparation on liver cirrhosis rat model advanced glycation end products（AGEs）.Methods The composite factor method CCl4 cirrhotic rats manufacturing to AGEs content in liver homogenates and liver pathology as the index,using enzyme-linked immunosorbent assay（ELISA） quantitative analysis of liver tissue homogenate content of AGEs.Results Ruhuang preparation can significantly reduce the milk of rats with liver AGEs concentration levels（P0.05）;to improve the treatment group and model group to prevent liver cirrhosis and fibrosis,inflammatory cell infiltration,including the prevention of liver tissue The pathological changes were improved.Conclusion Ruhuang preparation can reduce the level of AGEs in liver tissue,is beneficial for the improvement of liver cirrhosis.
出处
《湖北中医学院学报》
2010年第6期11-13,共3页
Journal of Hubei College of Traditional Chinese Medicine
关键词
乳黄制剂
肝硬化
晚期糖基化终末产物
实验研究
Ruhuang Preparation
Cirrhosis
Advanced Glycation End Products
Experimental study
